HLX-26

N/A

Report date: 2023/05/04 14:28:41

Base Information

Drug NameHLX-26
Drug Alias Name重组抗LAG-3人源化单克隆抗体注射液HLX-26
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionLymphocyte activation gene 3 protein inhibitors
TargetsLymphocyte activation gene 3 protein
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungColorectal Neoplasms +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesShanghai Henlius Biologics Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShanghai Henlius Biologics Co LtdShanghai Henlius Biotech IncShanghai Henlius Biopharmaceuticals Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungLymphoma
Inactive IndicationsColorectal Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A